1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- AbbVie Inc.
- Amgen Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- MORE
Global Behcet's Disease Therapeutics Market: About this market
The Behcet's disease therapeutics market analysis considers sales from both small molecules and biologics. Our analysis also considers the sales of Behcet's disease therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as cost-effectiveness and strong penetration will play a significant role in the small molecules segment to maintain its market position. Also, our global Behcet's disease therapeutics market report looks at factors such as heavy use of off-label drugs, special drug designations, and increasing research funding for rare diseases. However, difficulty in diagnosis, adverse effects of small molecule-based drugs, and idiopathic nature of the disease may hamper the growth of the Behcet's disease therapeutics industry over the forecast period.
Global Behcet's Disease Therapeutics Market: Overview
Increasing research funding for rare diseases
Currently, global Behcet's disease therapeutics market has only two approved drugs for the treatment of the condition. Although the condition is rare, its increasing prevalence is leading to the intense R&D novel therapies by vendors and research institutes for the development of treatment for Behcet's disease. These vendors and institutes rely on grants from organizations that provide research funding. These organizations aim to improve the quality of life of patients’ vasculitis and associated diseases and increases awareness about rare diseases among public and medical practitioners. This will lead to the expansion of the global Behcet's disease therapeutics market at a CAGR of over 6% during the forecast period.
The advent of novel therapies
Behcet’s disease is also considered to be associated with genetic mutations and autoimmune disorders, for which the market has a huge unmet need. The reason for the growing preference for a novel therapy for the treatment of life-threatening disorders is its curative nature. The huge unmet need has attracted various pharmaceutical companies and academic institutions to invest substantially in the R&D of novel therapies for the treatment of Behcet’s disease. Factors such as recent advances in the research of these novel therapies are attracting the companies to start the research on gene therapy for Behcet’s disease. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global Behcet's disease therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Behcet's disease therapeutics manufacturers. These include AbbVie Inc., Amgen Inc., Celgene Corp., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.
Also, Behcet's disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The Behcet's disease therapeutics market analysis considers sales from both small molecules and biologics. Our analysis also considers the sales of Behcet's disease therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as cost-effectiveness and strong penetration will play a significant role in the small molecules segment to maintain its market position. Also, our global Behcet's disease therapeutics market report looks at factors such as heavy use of off-label drugs, special drug designations, and increasing research funding for rare diseases. However, difficulty in diagnosis, adverse effects of small molecule-based drugs, and idiopathic nature of the disease may hamper the growth of the Behcet's disease therapeutics industry over the forecast period.
Global Behcet's Disease Therapeutics Market: Overview
Increasing research funding for rare diseases
Currently, global Behcet's disease therapeutics market has only two approved drugs for the treatment of the condition. Although the condition is rare, its increasing prevalence is leading to the intense R&D novel therapies by vendors and research institutes for the development of treatment for Behcet's disease. These vendors and institutes rely on grants from organizations that provide research funding. These organizations aim to improve the quality of life of patients’ vasculitis and associated diseases and increases awareness about rare diseases among public and medical practitioners. This will lead to the expansion of the global Behcet's disease therapeutics market at a CAGR of over 6% during the forecast period.
The advent of novel therapies
Behcet’s disease is also considered to be associated with genetic mutations and autoimmune disorders, for which the market has a huge unmet need. The reason for the growing preference for a novel therapy for the treatment of life-threatening disorders is its curative nature. The huge unmet need has attracted various pharmaceutical companies and academic institutions to invest substantially in the R&D of novel therapies for the treatment of Behcet’s disease. Factors such as recent advances in the research of these novel therapies are attracting the companies to start the research on gene therapy for Behcet’s disease. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global Behcet's disease therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Behcet's disease therapeutics manufacturers. These include AbbVie Inc., Amgen Inc., Celgene Corp., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.
Also, Behcet's disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- AbbVie Inc.
- Amgen Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Drug designations
Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet’s disease
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AbbVie Inc. - Vendor overview
Exhibit 51: AbbVie Inc. - Business segments
Exhibit 52: AbbVie Inc. - Organizational developments
Exhibit 53: AbbVie Inc. - Geographic focus
Exhibit 54: AbbVie Inc. - Key offerings
Exhibit 55: AbbVie Inc. - Key customers
Exhibit 56: Amgen Inc. - Vendor overview
Exhibit 57: Amgen Inc. - Product segments
Exhibit 58: Amgen Inc. - Organizational developments
Exhibit 59: Amgen Inc. - Geographic focus
Exhibit 60: Amgen Inc. - Key offerings
Exhibit 61: Amgen Inc. - Key customers
Exhibit 62: Celgene Corp. - Vendor overview
Exhibit 63: Celgene Corp. - Business segments
Exhibit 64: Celgene Corp. - Organizational developments
Exhibit 65: Celgene Corp. - Geographic focus
Exhibit 66: Celgene Corp. - Key offerings
Exhibit 67: Celgene Corp. - Key customers
Exhibit 68: Eisai Co. Ltd. - Vendor overview
Exhibit 69: Eisai Co. Ltd. - Business segments
Exhibit 70: Eisai Co. Ltd. - Organizational developments
Exhibit 71: Eisai Co. Ltd. - Geographic focus
Exhibit 72: Eisai Co. Ltd. - Segment focus
Exhibit 73: Eisai Co. Ltd. - Key offerings
Exhibit 74: Eisai Co. Ltd. - Key customers
Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 82: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 83: Johnson & Johnson Services, Inc. - Business segments
Exhibit 84: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 85: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 86: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 87: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 88: Johnson & Johnson Services, Inc. - Key customers
Exhibit 89: Mylan NV - Vendor overview
Exhibit 90: Mylan NV - Product segments
Exhibit 91: Mylan NV - Organizational developments
Exhibit 92: Mylan NV - Geographic focus
Exhibit 93: Mylan NV - Segment focus
Exhibit 94: Mylan NV - Key offerings
Exhibit 95: Mylan NV - Key customers
Exhibit 96: Novartis AG - Vendor overview
Exhibit 97: Novartis AG - Business segments
Exhibit 98: Novartis AG - Organizational developments
Exhibit 99: Novartis AG - Geographic focus
Exhibit 100: Novartis AG - Segment focus
Exhibit 101: Novartis AG - Key offerings
Exhibit 102: Novartis AG - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Small molecules - Market size and forecast 2018-2023
- Biologics - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie Inc.
- Amgen Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Drug designations
Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet’s disease
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AbbVie Inc. - Vendor overview
Exhibit 51: AbbVie Inc. - Business segments
Exhibit 52: AbbVie Inc. - Organizational developments
Exhibit 53: AbbVie Inc. - Geographic focus
Exhibit 54: AbbVie Inc. - Key offerings
Exhibit 55: AbbVie Inc. - Key customers
Exhibit 56: Amgen Inc. - Vendor overview
Exhibit 57: Amgen Inc. - Product segments
Exhibit 58: Amgen Inc. - Organizational developments
Exhibit 59: Amgen Inc. - Geographic focus
Exhibit 60: Amgen Inc. - Key offerings
Exhibit 61: Amgen Inc. - Key customers
Exhibit 62: Celgene Corp. - Vendor overview
Exhibit 63: Celgene Corp. - Business segments
Exhibit 64: Celgene Corp. - Organizational developments
Exhibit 65: Celgene Corp. - Geographic focus
Exhibit 66: Celgene Corp. - Key offerings
Exhibit 67: Celgene Corp. - Key customers
Exhibit 68: Eisai Co. Ltd. - Vendor overview
Exhibit 69: Eisai Co. Ltd. - Business segments
Exhibit 70: Eisai Co. Ltd. - Organizational developments
Exhibit 71: Eisai Co. Ltd. - Geographic focus
Exhibit 72: Eisai Co. Ltd. - Segment focus
Exhibit 73: Eisai Co. Ltd. - Key offerings
Exhibit 74: Eisai Co. Ltd. - Key customers
Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 82: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 83: Johnson & Johnson Services, Inc. - Business segments
Exhibit 84: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 85: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 86: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 87: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 88: Johnson & Johnson Services, Inc. - Key customers
Exhibit 89: Mylan NV - Vendor overview
Exhibit 90: Mylan NV - Product segments
Exhibit 91: Mylan NV - Organizational developments
Exhibit 92: Mylan NV - Geographic focus
Exhibit 93: Mylan NV - Segment focus
Exhibit 94: Mylan NV - Key offerings
Exhibit 95: Mylan NV - Key customers
Exhibit 96: Novartis AG - Vendor overview
Exhibit 97: Novartis AG - Business segments
Exhibit 98: Novartis AG - Organizational developments
Exhibit 99: Novartis AG - Geographic focus
Exhibit 100: Novartis AG - Segment focus
Exhibit 101: Novartis AG - Key offerings
Exhibit 102: Novartis AG - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- AbbVie Inc.
- Amgen Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- MORE
The following companies are recognised as the key players in the global Behcet's disease therapeutics market: AbbVie Inc., Amgen Inc., Celgene Corp., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of novel therapies.”
According to the report, one of the major drivers for this market is the increasing research funding for rare diseases.
Further, the report states that one of the major factors hindering the growth of this market is the idiopathic nature of the disease.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of novel therapies.”
According to the report, one of the major drivers for this market is the increasing research funding for rare diseases.
Further, the report states that one of the major factors hindering the growth of this market is the idiopathic nature of the disease.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- AbbVie Inc.
- Amgen Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
